**Patient Discharge Summary**

**Patient Information:**
Name: John Doe
Date of Birth: January 1, 1980
Admission Date: March 10, 2023
Discharge Date: March 25, 2023
Hospital Stay Duration: 15 days

**Medical History:**
The patient was admitted to the endocrinology unit on March 10, 2023, with a diagnosis of type 2 diabetes. The patient had been experiencing symptoms of polydipsia, polyuria, and fatigue for several months prior to admission. Upon admission, the patient's fasting plasma glucose (FPG) level was 230 mg/dL, and his glycosylated hemoglobin (HbA1C) level was 8.2%.

**Hospital Course:**
During the patient's hospital stay, he underwent a comprehensive evaluation, including a physical examination, laboratory tests, and imaging studies. The patient's diagnosis of type 2 diabetes was confirmed based on his FPG level and HbA1C level.

On March 12, 2023, the patient underwent an oral glucose tolerance test (OGTT), which showed a glucose level of 250 mg/dL at 2 hours. This confirmed the diagnosis of type 2 diabetes.

The patient was started on metformin 500 mg orally twice daily on March 15, 2023. He was also prescribed a GLP-1 receptor agonist, semaglutide 2.4 mg, subcutaneously once weekly, on March 17, 2023.

**Treatment and Education:**
The patient received comprehensive education on diabetes, including its causes, symptoms, and signs of hypoglycemia and hyperglycemia. He was also educated on the importance of regular blood glucose monitoring, insulin dose adjustments, and carbohydrate intake.

The patient was advised to follow a personalized diet plan, focusing on whole foods and high-quality carbohydrates, and to maintain a physical activity level of at least 150 minutes per week.

**Medications:**
* Metformin 500 mg orally twice daily
* Semaglutide 2.4 mg subcutaneously once weekly
* Insulin therapy was initiated on March 20, 2023, with a dose of 20 units of insulin glargine at bedtime

**Follow-up:**
The patient was discharged on March 25, 2023, with instructions to follow up with his primary care physician in 2 weeks. He was advised to return to the hospital if he experiences any symptoms of hypoglycemia or hyperglycemia, or if he has any concerns about his medication regimen.

**Outpatient Recommendations:**
* Regular follow-up with primary care physician every 2 weeks
* Regular blood glucose monitoring and insulin dose adjustments as needed
* Maintenance of a healthy diet and regular physical activity
* Regular podiatric care to prevent foot complications
* Vaccination against Streptococcus pneumoniae, influenza virus, hepatitis B, varicella, and SARS-CoV-2
* Consideration of medical devices and surgical treatments for obesity, such as sleeve gastrectomy or gastric bypass, for weight loss and improvement in glucose control.

**Final Disposition:**
The patient was discharged in stable condition, with a plan for continued treatment and follow-up in the outpatient setting.